ClinicalTrials.gg
Active, not recruitingNCT06926933NESTUpdated Jul 8, 2026

Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty

A Phase 4 interventional study of Eligard® 45 mg in CPP, sponsored by HanAll BioPharma Co., Ltd.. Active, not recruiting at 9 sites in South Korea. Open to participants aged 4 Years to 9 Years. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by HanAll BioPharma Co., Ltd. (part of Daewoong Pharmaceutical Co. LTD.) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Dec 2024, registered Apr 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
4 Years to 9 Years
Sex
All
01

Study summary

This study is a multicenter, open-label, single-group, and phase 4 study to evaluate the efficacy and safety of 45 mg of leuprolide acetate in CPP.

Screening tests are performed after the subject agrees in writing to participate in the clinical trial, and subjects who meet the inclusion criteria and do not fall under the exclusion criteria are enrolled in the study. The target patients in this study are pediatric patients who have been diagnosed with CPP but have not yet received GnRH agonist treatment, and all subjects perform GnRH stimulation tests to confirm their CPP diagnosis.

02

Conditions studied

  • CPP
03

In context

Lead sponsor

HanAll BioPharma Co., Ltd. is the lead sponsor of 16 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 9 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pubertal-type LH response following an abbreviated GnRH stimulation test before treatment initiation > 5 IU/L
  2. A subject manifested with central precocious puberty according to the following criteria Age : Boy (4 years of age or older \~ under 9 years of age) Girl (4 years of age or older \~ under 8 years of age) Tanner Stage : Level 2 or higher
  3. Based on baseline visit (Day 0), those under the age of 10 for boys and those under the age of 9 for girls
  4. Confirmed diagnosis of CPP within 12 months of Baseline Visit (Day 0) but have not received prior GnRH agonist treatment for CPP
  5. Children with a body weight of more than 20 kg at screening
  6. Children have a bone age that is ≥1 year older than their chronological age at screening
  7. A signed written consent form by a legal representative who has been informed about this study

Exclusion criteria

Exclusion Criteria:

  1. Gonadotropin-independent (peripheral) precocious puberty: extra pituitary secretion of gonadotropins or gonadotropin-independent gonadal or adrenal sex secretion
  2. Prior or current GnRH treatment for CPP
  3. Non-progressing isolated premature thelarche
  4. Presence of an unstable intracranial tumor or an intracranial tumor requiring neurosurgery or cerebral irradiation. Subjects with hamartomas not requiring surgery are eligible.
  5. Prior (within 12 weeks of Screening) use of medications

    • Hormonal agonists (Estrogen, Progesterone, FSH, LH, Testosterone etc.)
    • Hormonal antagonists (Anti-Estrogen agents, Anti-Androgen agents)
    • Steroid use (except for mild topical steroids, oral steroids are allowed within 30 days)
    • Herbal Medicines
  6. Prior or current therapy with growth hormone
  7. Major medical or psychiatric illness that could interfere with study visits
  8. Diagnosis of short stature (i.e. 2 standard deviations (SD) below the mean height for age or 3rd percentile for age)
  9. Pregnant or likely pregnant women (Positive urine pregnancy test), nursing women
  10. Known to GnRH or related compounds
  11. Any other medical condition or serious intercurrent illness that, in the opinion of the investigator, may make it undesirable for the subject to participate in the study
  12. Any other condition(s) which could significantly interfere with Protocol compliance
  13. Treatment with an product within 5 half-lives of that product in prior clinical studies before the baseline visit (Day 0)
  14. Known history of seizures, epilepsy, and/or central nervous system disorders that may be associated with seizures or convulsions
  15. Prior (within 6 months of Baseline (Day 0)) or current use of medications that, per investigator opinion, have been associated with seizures or convulsions
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Eligard® 45 mg

    SC injection of study drug (45 mg of leuprolide acetate for injectable suspensions)

    Drug: Eligard® 45 mg

Interventions

06

What researchers measure

Primary outcomes

  1. The percentage (%) of subjects with serum LH concentrations < 4 IU/L following an GnRH stimulation test

    Blood samples for serum LH concentrations (as appropriate) will be collected at the appropriate assessment times and analyzed by a central laboratory.

    Time frame: at week 24

Secondary outcomes

  1. The percentage (%) of subjects with suppressed serum LH concentrations (< 4 IU/L) 30-minutes post GnRH stimulation test

    Blood samples for serum LH concentrations (as appropriate) will be collected at the appropriate assessment times and analyzed by a central laboratory.

    Time frame: at week 12, 48, 72, 96

  2. The percentage (%) of subjects with suppressed serum FSH (< 2.5 mIU/mL), estradiol (< 20 pg/mL, for girl) or testosterone (< 30 ng/dL, for boy)

    Sexual development in puberty will be assessed by Tanner staging

    Time frame: at week 12, 24, 48, 72, 96

  3. The percentage of subject of Tanner stage (including menstruation)

    Sexual development in puberty will be assessed by Tanner staging

    Time frame: at week 12, 24, 48, 72, 96

  4. Height velocity (growth rate)

    Annualized Height Velocity

    Time frame: at week 12, 24, 48, 72, 96

  5. The ratio of bone age and chronological age

    A single X-ray of the non-dominant hand and wrist will be obtained periodically

    Time frame: at week 12, 24, 48, 72, 96

07

Study locations

9 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Jun 2026, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2025
First posted
Apr 15, 2025
StartActual
Dec 12, 2024
Primary completionActual
Jun 15, 2026
CompletionEst.
Nov 30, 2027
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06926933
Responsible party
Sponsor
First posted
Apr 15, 2025
Start date
Dec 12, 2024
Primary completion
Jun 15, 2026
Completion
Nov 30, 2027 (estimated)
Last update
Jul 8, 2026

Study contacts

Eunhee Lee
study director · Hanall Biopharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Luprolide acetate gel depot

Start the discussion